Neuronetics, Inc. (STIM)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 2
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3, so no long entry can be admitted; both entry types were nevertheless evaluated - a pullback/oversold limit is disqualified as countertrend (price 1.39 below SMA50 2.35 with MACD -0.17 < 0) and a breakout buy-stop above the settled 2026-11-13 high 1.44 is disqualified by overnight-gap risk (max overnight gap 19.1% versus the 5% cap), so no qualifying setup exists.
Company overview
Neuronetics, Inc. is a medical technology company focused on developing and distributing solutions for neurohealth conditions. Its primary product, the NeuroStar Advanced Therapy System, offers non-surgical treatment for major depressive disorder using transcranial magnetic stimulation. The company operates from Malvern, Pennsylvania, and sells directly to psychiatrists.
Fundamental
very weakNeuronetics faces financial distress with a going-concern warning, covenant issues, and recent dilution overshadowing operational improvements.
Too risky to invest at this juncture: an explicit going-concern qualification in the latest 10-Q, a projected breach of the March 2027 revenue covenant under a lien-secured 11.5% credit facility, negative EBITDA and operating cash flow, and roughly a quarter of dilution from an equity offering priced at $1.60 that closed days ago. Operating trends are genuinely improving - Q3 2026 produced the first positive quarterly operating income and positive quarterly operating cash flow in the recent record - but the balance sheet, the covenant timeline and insider selling dominate the near-term risk.
Sentiment
very weakMedia sentiment is mixed with concerns over dilution and debt, while retail sentiment remains indeterminate.
Dominant near-term driver is the announced $30M underwritten offering priced at $1.60 on 2026-11-11 (18.75M shares plus over-allotment, roughly 24% dilution, proceeds earmarked to repay Perceptive), which closed 2026-11-12 and has left shares at $1.39, about 13% below the deal price; Q3 2026 (announced: revenue +12.5% to $42.0M, adjusted EBITDA +$1.9M) is a genuine but secondary bullish leg the tape did not reward. The sentiment delta is indeterminate because baseline scored coverage holds only one unique item, and the Red-Flag Screen is not clean: an explicit going-concern conclusion in the 2026-11-04 10-Q combined with a distress-context dilutive raise fires the severe red-flag cap.
Technical
weakThe stock is in a strong downtrend with oversold conditions but no clear reversal signals.
Chart quality is weak and dominated by trend, not by the bounce: price 1.39 sits below SMA20 2.08, SMA50 2.35, SMA200 1.87, EMA9 1.85, EMA21 2.04, WMA9 1.82, WMA21 2.03, DEMA14 1.75 and TEMA14 1.63 - a complete bearish moving-average stack roughly 60% below the 3.44 year high. MACD is negative and expanding (-0.17/-0.08, histogram -0.08) and ADX14 24.57 read together with price below every MA describes a strong, only slowly decelerating downtrend rather than a base. RSI14 31.59 and Williams %R -89.73 are oversold but have not turned up, so the only bullish evidence is a single heavy-volume reversal session (2026-11-13, +14.9%, close 1.39 above the session VWAP 1.31 on 16.3M shares) off the 1.13/1.20 low. That is a bounce, not a trend change, hence technicalScore 2. Independent of the chart, fundamentalScore 1 and qualitativeScore 1 both breach the required floor of 3, so the action is Do Nothing; both a pullback limit (countertrend by rule) and a breakout buy-stop (overnight-gap gate) were evaluated and rejected.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

